EMA’s Revised ATMP Evaluation Procedure Gets Industry Thumbs Up
Executive Summary
EU pharmaceutical companies believe the revisions the European Medicines Agency has made to its procedure for evaluating gene and cell therapy products addresses the specific needs of advanced therapy developers. They have also welcomed, in principle, a revised EMA guideline on the follow-up and risk management of such products.